ANVS Jul 2024 37.500 put
| Previous Close | 23.00 |
| Open | N/A |
| Bid | 29.00 |
| Ask | 32.00 |
| Strike | 37.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 23.00 - 23.00 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 10 |
GlobeNewswireAnnovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
Changes in MMSE after treatment with 10mg or 20mg buntanetap compared to baseline and placebo Figure 1. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo Figure 2. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with PIGD Figure 3. Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s pati
ZacksMerck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
ZacksCASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
